Search Result

Results for "

Pancreatic Cancer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) ADC Payload (1) Akt (8) Amylases (2) Anaplastic lymphoma kinase (ALK) (1) Antibiotic (2) Antibody-Drug Conjugates (ADCs) (4) AP-1 (1) Apoptosis (54) Aryl Hydrocarbon Receptor (4) ATTECs (1) Autophagy (12) Bacterial (6) Bcl-2 Family (3) Biochemical Assay Reagents (2) Bombesin Receptor (1) c-Met/HGFR (2) c-Myc (4) Calcium Channel (2) Carbonic Anhydrase (1) Casein Kinase (1) Caspase (8) Cathepsin (1) CCR (1) CDK (10) Checkpoint Kinase (Chk) (1) Cholecystokinin Receptor (2) Complement System (1) COX (2) CXCR (1) Cyclophilin (1) Cytochrome P450 (2) Deubiquitinase (1) DNA-PK (3) DNA/RNA Synthesis (7) Drug Derivative (1) E1/E2/E3 Enzyme (1) EGFR (7) Endogenous Metabolite (8) Ephrin Receptor (1) Epigenetic Reader Domain (4) ERK (6) Estrogen Receptor/ERR (5) Eukaryotic Initiation Factor (eIF) (1) FAK (1) FAP (1) Farnesyl Transferase (1) Fat Mass and Obesity-associated Protein (FTO) (1) Ferroptosis (5) Fluorescent Dye (4) Fungal (6) G-quadruplex (2) GLUT (2) Glutaminase (1) Glutathione Peroxidase (1) Glycosidases (2) GSK-3 (4) HBV (2) HDAC (5) Hedgehog (2) HIF/HIF Prolyl-Hydroxylase (2) Histamine Receptor (1) Histone Acetyltransferase (2) Histone Methyltransferase (2) HIV (4) HSP (2) HSV (3) HuR (1) ICMT (1) IGF-1R (3) IKK (1) Influenza Virus (1) Integrin (1) Interleukin Related (1) IRAK (1) JAK (1) Keap1-Nrf2 (1) Lactate Dehydrogenase (4) Lipoxygenase (1) LPL Receptor (1) LXR (1) MAP4K (1) MDM-2/p53 (9) MEK (1) Methionine Adenosyltransferase (MAT) (4) Microtubule/Tubulin (2) Mitochondrial Metabolism (2) Molecular Glues (1) mTOR (3) Mucin (2) Na+/H+ Exchanger (NHE) (2) NEKs (1) Neurotensin Receptor (1) NF-κB (4) Notch (2) Nucleoside Antimetabolite/Analog (1) Orexin Receptor (OX Receptor) (2) Orphan Receptor (1) Orthopoxvirus (1) Oxidative Phosphorylation (2) p38 MAPK (1) Parasite (3) PARP (7) PD-1/PD-L1 (1) Phosphatase (2) Phosphodiesterase (PDE) (1) PI3K (6) Pim (1) PIN1 (1) PKC (1) Porcupine (1) Potassium Channel (1) Prostaglandin Receptor (2) PROTACs (3) Proton Pump (2) Pyroptosis (2) Radionuclide-Drug Conjugates (RDCs) (1) Raf (3) Ras (22) Reactive Oxygen Species (8) Ribosomal S6 Kinase (RSK) (2) RIP kinase (2) ROR (1) SHP2 (2) Sirtuin (1) Somatostatin Receptor (3) STAT (7) Survivin (1) TAM Receptor (1) TMV (1) Toll-like Receptor (TLR) (2) Transmembrane Glycoprotein (1) Trk Receptor (2) TROP2 (2) TRP Channel (2) VEGFR (4) Virus Protease (1) Wee1 (1) Wnt (4) γ-secretase (1)
By Research Areas:	Cancer (253) Cardiovascular Disease (5) Endocrinology (6) Infection (11) Inflammation/Immunology (15) Metabolic Disease (11) Neurological Disease (10)
Click Chemistry:	Azide (1) Alkynes (1)
Oligonucleotides:	Aptamers (4)

259

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Click Chemistry

Oligonucleotides

SIRT6-IN-3	Sirtuin HDAC Akt mTOR Ribosomal S6 Kinase (RSK) ERK	Neurological Disease Inflammation/Immunology Endocrinology Cancer
SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC₅₀=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cells proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) via blocking the DNA damage repair pathway. SIRT6-IN-3 is used in pancreatic cancer research .

Clivatuzumab	Mucin	Cancer
Clivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers .

NIEA	Others	Cancer
NIEA is a potent carcinogen that induce pancreatic cancer, esophageal cancer and hepatocellular carcinoma .

Hedgehog IN-7	Hedgehog	Cancer
Hedgehog IN-7 (Compound 8g), a purine derivative, acts as an inhibitor of Hedgehog, capable of reducing the expression of Hedgehog genes and inhibiting Hedgehog signaling. Hedgehog IN-7 has significant cytotoxicity and selectivity towards the Hedgehog pathway-dependent pancreatic cancer cell Mia-PaCa-2 cells and can be used in the research of pancreatic cancer .

EAD1	Autophagy Apoptosis	Cancer
EAD1 is a potent autophagy inhibitor with antiproliferative activity in lung and pancreatic cancer cells. EAD1 also induces apoptosis .

S100A2-p53-IN-1	MDM-2/p53	Cancer
S100A2-p53-IN-1 (compound 51) is a S100A2-p53 interactions inhibitor. S100A2 is a Ca ²⁺ binding protein with implications in cell signaling and is known to be upregulated in pancreatic cancer. S100A2-p53-IN-1 can inhibit the growth of the MiaPaCa-2 pancreatic cancer cell line (GI ⁵⁰ of 1.2-3.4 μM) .

EGFR-IN-105	EGFR Apoptosis	Cancer
EGFR-IN-105 (Compound 5b) is an EGFR2 inhibitor with an IC₅₀ value of 0.68 μM. EGFR-IN-105 exhibits anticancer activity and can induce apoptosis in cancer cells, which is used in the research of pancreatic cancer .

α-Thevetin B	Others	Cardiovascular Disease Cancer
α-Thevetin B（Compound 24） is a cardiac glycoside that can be isolated from Thevetia peruviana. α-Thevetin B（Compound 24） can be used in lung cancer, gastric cancer and pancreatic cancer research .

pan-KRAS-IN-15	Ras	Cancer
pan-KRAS-IN-15 (compound 58) is a pan-KRAS inhibitor. pan-KRAS-IN-15 can be used in pancreatic cancer research .

FAK-IN-6	FAK	Cancer
FAK-IN-6 is a potent FAK inhibitor with an IC₅₀ value of 1.415 nM. FAK-IN-6 has anti-proliferative activity against certain cancer cell lines. FAK-IN-6 can be used for researching pancreatic cancer .

SP-141 1 Publications Verification	MDM-2/p53	Cancer
SP-141 is a specific inhibitor of MDM2. SP-141 promotes MDM2 auto-ubiquitination and degradation. SP-141 might be used for the research of pancreatic cancer and breast cancer cells .

Glychionide A	Apoptosis Autophagy	Cancer
Glychionide A is a flavonoside that can be found in the roots of Glychirriza glabra. Glychionide A promotes apoptosis and autophagy of PANC-1 pancreatic cancer cells. Glychionide A can be used for the research of cancer .

(+)-Matairesinol	Others	Others
(+)-Matairesinol is a lignan. (+)-Matairesinol has no cytotoxic activity for human pancreatic PANC-1 cancer cells .

Gastrazole JB95008	Cholecystokinin Receptor	Cancer
Gastrazole (JB95008) is potent and selective CCK2/gastrin receptor antagonist. Gastrazole can decrease the level of gastric acid. Gastrazole inhibits the Gastrin-stimulated growth of pancreatic cancer .

Phellodendrine chloride	Autophagy	Cancer
Phellodendrine chloride is a plant alkaloid found in Phellodendron amurense. Phellodendrine chloride suppresses the proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis . Phellodendrine chloride promotes autophagy by regulating the AMPK/mTOR pathway and reduce the intestinal damage of ulcerative colitis .

Spiclomazine Clospirazine	Ras	Cancer
Spiclomazine (Clospirazine) is a potent mutant KRAS(G12C) inhibitor that selectively inhibits mutant KRAS-driven pancreatic cancer. Spiclomazine can eliminate KRas-GTP levels in KRAS-driven pancreatic cancer and effectively inhibit RAS-mediated signaling. Spiclomazine significantly inhibits tumor progression in mouse renal capsule xenotransplantation models .

Targefrin	Ephrin Receptor	Cancer
Targefrin is a potent EphA2-targeting agent, acts as an antagonist. Targefrin binds EphA2-LBD with 21 nM dissociation constant and an IC₅₀ value of 10.8 nM. Targefrin induces cellular receptor internalization and degradation in several pancreatic cancer cell lines .

WEE1-IN-8	Wee1	Cancer
WEE1-IN-8 (Compound 55) is a selective WEE1 inhibitor, with an IC₅₀ of 0.98 nM. WEE1-IN-8 (Compound 55) can be used for the research of Pancreatic cancer, Ovarian cancer, Colorectal cancer, Uterine serous carcinoma, etc .

NSC 48160	Apoptosis	Cancer
NSC 48160 inhibits the growth of the pancreatic cancer cells with IC₅₀s of 84.3 μM for CPFAC-1 and 94.5 μM for BxPC-3. NSC 48160 also induces pancreatic cancer cell apoptosis. NSC 48160 can improve metabolic syndromes, such as NASH, obesity and lipid metabolism disorders .

Carbidopa 1 Publications Verification (S)-(-)-Carbidopa	Aryl Hydrocarbon Receptor	Neurological Disease Cancer
Carbidopa ((S)-(-)-Carbidopa), a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa inhibits pancreatic cancer cell and tumor growth .

Carbidopa monohydrate 1 Publications Verification (S)-(-)-Carbidopa monohydrate	Aryl Hydrocarbon Receptor	Neurological Disease Cancer
Carbidopa ((S)-(-)-Carbidopa) monohydrate, a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa monohydrate is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa monohydrate inhibits pancreatic cancer cell and tumor growth .

Nardoguaianone K 10-epi-Nardoguaianone J	Others	Cancer
Nardoguaianone K, a guaiane-type compound, can be isolated from Nardostachys chinensis roots. Nardoguaianone K cam be used in the research of pancreatic cancer .

Phellodendrine chloride (Standard)	Autophagy	Cancer
Phellodendrine (chloride) (Standard) is the analytical standard of Phellodendrine (chloride). This product is intended for research and analytical applications. Phellodendrine chloride is a plant alkaloid found in Phellodendron amurense. Phellodendrine chloride suppresses the proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis . Phellodendrine chloride promotes autophagy by regulating the AMPK/mTOR pathway and reduce the intestinal damage of ulcerative colitis .

MM41	G-quadruplex	Cancer
MM41 is a potent stabilizer of human telomeric and gene promoter DNA quadruplexes. MM41 is potently against the MIA PaCa-2 pancreatic cancer cell line with IC₅₀ value of <10 nM .

GSI-18	γ-secretase Notch	Cancer
GSI-18 is a γ-secretase inhibitor with anticancer activity. GSI-18 attenuates anchorage-independent growth in pancreatic cancer cells by inhibiting Notch signaling .

LDHA-IN-8	Lactate Dehydrogenase	Cancer
LDHA-IN-8 (Compound 6) is a lactate dehydrogenase (LDHA) inhibitor. LDHA-IN-8 inhibits LDHA catalysis of pyruvate in a dose-dependent manner (EC₅₀ value of 14.54 μM), reduces intracellular lactate levels, and increases intracellular reactive oxygen species (ROS) levels, thereby inhibiting the proliferation of pancreatic cancer cells and lung cancer cells. LDHA-IN-8 holds promise for research in the field of LDHA-related antitumor therapies .

Elpamotide	VEGFR	Cancer
Elpamotide is an epitope peptide derived from VEGFR2. Elpamotide induces cytotoxic T lymphocytes (CTLs) to kill VEGFR2-expressing endothelial cells. Elpamotide has potential immunostimulatory and antineoplastic activities. Elpamotide can be used in the research of cancer, such as pancreatic cancer .

YUM70 1 Publications Verification	HSP Apoptosis	Cancer
YUM70 is a potent and selective inhibitor of glucose-regulated protein 78 (GRP78), with an IC₅₀ of 1.5 μM for inhibiting GRP78 ATPase activity of the full-length protein. YUM70 induces endoplasmic reticulum (ER) stress-mediated apoptosis in pancreatic cancer. YUM70 also has in vivo efficacy in a pancreatic cancer xenograft model .

Cymarin	Parasite Potassium Channel	Others Cancer
Cymarin, a cardiac glycoside, potently inhibits the Palytoxin (PTX)-induced K ⁺ release (IC₅₀=0.42 μM). Cymarin reveals an antitumor activity against breast cancer and pancreatic cancer. Cymarin exhibits antifeedant and growth inhibitory effects as crop protectant .

BNT411	Toll-like Receptor (TLR)	Cancer
BNT411 is a selective TLR7 agonist that can induce the release of IFNa both in vivo and in vitro. BNT411 has anticancer activity and can be used in cancer research, including non-small cell lung cancer, pancreatic cancer, and untreated extensive-stage small cell lung cancer (ES-SCLC) .

KRAS inhibitor-10	Ras	Cancer
KRAS inhibitor-10 (compound 11) selectively and effectively inhibit RAS proteins, and particularly KRAS proteins. KRAS inhibitor-10 is an orally active anti-cancer agent and can be used for cancer research, such as pancreatic cancer, breast cancer, multiple myeloma, leukemia and lung cancer. KRAS inhibitor-10 is a tetrahydroisoquinoline compound (compound 11) extracted from patent WO2021005165 A1 .

FLQY2	Apoptosis	Cancer
FLQY2 is a camptothecin analog that exhibits outstanding antitumor efficacy against various solid tumors. FLQY2 possesses both in vitro and in vivo anti-pancreatic cancer activity, inhibiting cell proliferation, colony formation, inducing apoptosis, and causing cell cycle arrest at nanomolar concentrations .

Carbidopa (monohydrate) (Standard)	Aryl Hydrocarbon Receptor	Neurological Disease Cancer
Carbidopa (monohydrate) (Standard) is the analytical standard of Carbidopa (monohydrate). This product is intended for research and analytical applications. Carbidopa ((S)-(-)-Carbidopa) monohydrate, a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa monohydrate is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa monohydrate inhibits pancreatic cancer cell and tumor growth .

JI130	Notch	Cancer
JI130 (JI051 derivative ) is a stabilizer for the Hes1-PHB2 interaction. JI130 inhibits the ability of Hes1 to repress transcription. JI130 significantly reduces the tumor growth in a murine pancreatic tumor model and has the potential for managing pancreatic cancer .

FTO-IN-7	Fat Mass and Obesity-associated Protein (FTO)	Cancer
FTO-IN-7 is an inhibitor of FTO. FTO-IN-7 can be used in study Alzheimer's diseases, breast cancers, small-cell lung cancers,a human bone marrow striated muscle cancer, a pancreatic cancer, malignant glioblastoma .

SHP2-IN-22	SHP2	Cancer
SHP2-IN-22 is SHP2 allosteric inhibitor with an IC₅₀ value of 17.7 nM. SHP2-IN-22 inhibits the proliferation, migration, and invasion of MIA PaCa-2 pancreatic cancer cells. SHP2-IN-22 can be used for Kirsten rat sarcoma viral oncogene (KRAS) mutant cancer research .

DX3-234	Oxidative Phosphorylation Mitochondrial Metabolism	Cancer
DX3-234 is an oxidative phosphorylation (OXPHOS) inhibitor. DX3-234 shows significant tumor suppression in the Pan02 syngeneic model of pancreatic cancer .

Ensituximab Anti-MUC5AC Reference Antibody (ensituximab); NEO-102	Mucin Others	Cancer
Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer .

Nek2-IN-4	NEKs	Cancer
Nek2-IN-4 is a potent NEK2 inhibitor with an IC₅₀ value of 15 nM. Nek2-IN-4 inhibits cell proliferation. Nek2-IN-4 has the potential for the research of pancreatic cancer .

hGAPDH-IN-1	Others	Cancer
hGAPDH-IN-1, a 3-bromo-4,5-dihydroisoxazole derivative, is a specific and potent hGAPDH covalent inhibitor. hGAPDH-IN-1 reduces cancer cell growth in different pancreatic cancer cell lines.

KP372-1 2 Publications Verification	Akt Reactive Oxygen Species Apoptosis	Cancer
KP372-1 is an Akt inhibitor that inhibits proliferation and induces apoptosis and anoikis. KP372-1 is also an NQO1 redox cycling agent that causes DNA damage (including DNA breakage) by generating ROS. KP372-1 can be used in cancer research (such as head and neck squamous cell carcinoma (HNSCC) and pancreatic cancer) .

G9D-4	PROTACs Histone Methyltransferase	Cancer
G9D-4 is a potent PROTAC degrader of G9a, with the DC₅₀ value of 0.1 μM in PANC-1 cells and do not directly perturb GLP protein, with the DC₅₀ of ＞10 μM. G9D-4 plays an important role in pancreatic cancer research (Pink: Ligand for target protein G9a/GLP Inhibitor (HY-15273); Black: Linker; Blue: Ligand for E3 ligase (HY-10984)) .

CM03	DNA/RNA Synthesis	Cancer
CM03 is a potent DNA G-quadruplexes (G4s) ligand. CM03 can stabilise G4s, downregulating more G4-containing genes as well as increasing incidence of double-strand break events (DSBs) due to torsional strain on DNA and chromatin structure. CM03 has selective potency for pancreatic cancer cells .

PROTAC BRD4 Degrader-6	PROTACs Epigenetic Reader Domain Apoptosis c-Myc Caspase	Cancer
PROTAC BRD4 Degrader-6 (compound 32a) is a potent small-molecule BRD4PROTAC degrader with IC₅₀ value of 2.7 nM for BRD4 BD1. PROTAC BRD4 Degrader-6 potently degrades BRD4 protein and inhibits the expression of c-Myc. PROTAC BRD4 Degrader-6 inhibits the proliferation of pancreatic cancer cell line BxPC3 and induces apoptosis. PROTAC BRD4 Degrader-6 can be used for human pancreatic cancer research (Pink: Mivebresib (HY-100015); Black: linker, Azido-PEG1-CH2CO2H (HY-108369); Blue: Lenalidomide (HY-A0003)) .

Axl-IN-7	TAM Receptor	Cardiovascular Disease Inflammation/Immunology Cancer
Axl-IN-7 (Chemie 22) is a potent AXL inhibitor. Axl-IN-7 can be used for Axl-related diseases research, for example cancers (such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glial tumors), renal disease, immune system disorders, and cardiovascular disease .

KRAS G12C inhibitor 61	ERK Ras	Cancer
KRAS G12C inhibitor 61 (Example 3) inhibits phospho-ERK 1/2 in MIA PaCa-2 cells with an IC₅₀ value of 9 nM. KRAS G12C inhibitor 61 can be used for research of pancreatic, colorectal, and lung cancers .

Cat. No.	Product Name

HY-L077

Anti-Pancreatic Cancer Compound Library

3,012 compounds

Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer.

MCE offers a unique collection of 3,012 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-15096

MKT-077 5+ Cited Publications FJ-776	Dyes
MKT-077 (FJ-776), a highly water-soluble mitochondrial dye, has significant antitumor activity . MKT-077 exhibits low cytotoxicity, and inhibits broad-spectrum human cancer cell lines (colon cancer, breast cancer, pancreatic cancer). MKT-077 inhibits the growth of tumor in nude mice enograft tumor model. Ex/Em=488/543 nm .

HY-114491

Rineterkib

Fluorescent Dyes/Probes

Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .

HY-D2380

H2S probe 1	Fluorescent Dyes/Probes
H2S probe 1 (compound 1NND) is a derivative of nitrobenzoxadiazole (NBD) with antitumor activity. H2S probe 1 is cytotoxic to human pancreatic cancer cell MIA PaCa-2 (IC₅₀=77.9 nM) and has a high affinity for human telomeric G-quadruplex (G4) (K_d=1.72 μM). H2S probe 1 can be used in cancer research .

Cat. No.	Product Name	Type

HY-W013973

p-Terphenyl	Biochemical Assay Reagents
p-Terphenyl is a p-terphenyl that can be isolated from Aspergillus of the genus Thelephora. p-Terphenyl showed significant anti-tumor and anti-metastatic effects in xenograft models of gastric and pancreatic cancer. Derivatives of p-Terphenyl also have anti-inflammatory or anti-proliferative effects .

HY-W013973R

p-Terphenyl (Standard)

Biochemical Assay Reagents

p-Terphenyl (Standard) is the analytical standard of p-Terphenyl. This product is intended for research and analytical applications. p-Terphenyl is a p-terphenyl that can be isolated from Aspergillus of the genus Thelephora. p-Terphenyl showed significant anti-tumor and anti-metastatic effects in xenograft models of gastric and pancreatic cancer. Derivatives of p-Terphenyl also have anti-inflammatory or anti-proliferative effects .

Cat. No.	Product Name	Target	Research Area

HY-P3717

Targefrin	Ephrin Receptor	Cancer
Targefrin is a potent EphA2-targeting agent, acts as an antagonist. Targefrin binds EphA2-LBD with 21 nM dissociation constant and an IC₅₀ value of 10.8 nM. Targefrin induces cellular receptor internalization and degradation in several pancreatic cancer cell lines .

HY-P3509A

PNC-28 acetate	Peptides	Cancer
PNC-28 acetate is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 acetate can be used for pancreatic cancer research .

HY-P0234

Neurotensin 2 Publications Verification	Neurotensin Receptor	Endocrinology Cancer
Neurotensin, a gut tridecapeptide, acts as a potent cellular mitogen for various colorectal and pancreatic cancers which possess high-affinity neurotensin receptors (NTR).

HY-P5021

Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) c(RGDfE)	Biochemical Assay Reagents	Cancer
Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) (c(RGDfE)) is a cyclic RGD peptide that serves as a conjugated multifunctional nanodrug delivery system to target Gemcitabine to pancreatic cancer cells. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) can be used in cancer research .

HY-P3448

Certepetide CEND-1; iRGD; LSTA1	Integrin Complement System	Cancer
Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors .

HY-106374

Elpamotide	VEGFR	Cancer
Elpamotide is an epitope peptide derived from VEGFR2. Elpamotide induces cytotoxic T lymphocytes (CTLs) to kill VEGFR2-expressing endothelial cells. Elpamotide has potential immunostimulatory and antineoplastic activities. Elpamotide can be used in the research of cancer, such as pancreatic cancer .

HY-P3509

PNC-28	Peptides	Cancer
PNC-28 is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 can be used for pancreatic cancer research .

HY-P3058

Ederimotide WT-1 A1	Peptides	Cancer
Ederimotide(WT-1 A1) can be used as a potential target for studying pancreatic cancer .

HY-P5520

GB-6	Bombesin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
GB-6 is a short linear peptide that targets the gastrin releasing peptide receptor (GRPR). GRPR is overexpressed in pancreatic cancer. Based on the tumor selectivity and tumor-specific accumulation properties of GB-6, GB-6 labeled with near infrared (NIR) fluorescent dyes or radionuclide netium-99m (99mTc) can be used as a high-contrast imaging probe. GB-6 has excellent in vivo stability, with tumor to pancreatic and intestinal fluorescence signal ratios of 5.2 and 6.3, respectively, in SW199 0 subcutaneous xenograft models. GB-6 can rapidly target tumors and accurately delineate tumor boundaries, which has broad application prospects .

Cat. No.	Product Name

HY-K6110

*Human Pancreatic* Cancer Organoid Kit**
MCE Human Pancreatic Cancer Organoid Kit contains Pancreatic Cancer Organoid Basal Medium A, Pancreatic Cancer Organoid Supplement B (50×), Pancreatic Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human pancreatic cancer organoid.

Cat. No.	Product Name	Target	Research Area

HY-P99537

Ulenistamab PBP1510	Inhibitory Antibodies	Cancer
Ulenistamab (PBP1510) is a first-in-class hunamised IgG1 monoclonal antibody targeting pancreatic adenocarcinoma upregulated factor (PAUF). Ulenistamab can be used for pancreatic cancer (PC) research .

HY-P99968

Clivatuzumab	Mucin	Cancer
Clivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers .

HY-P99362

Ensituximab Anti-MUC5AC Reference Antibody (ensituximab); NEO-102	Mucin Inhibitory Antibodies	Cancer
Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer .

HY-P99275

Patritumab 1 Publications Verification Human Anti-ERBB3 Recombinant Antibody	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-P99379

Nidanilimab (Nadunolimab) CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)	Interleukin Related	Cancer
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a K_d value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .

HY-P9978

Toripalimab	PD-1/PD-L1	Cancer
Toripalimab is the first domestic anti-tumor PD-1 antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .

HY-P99049

Sotigalimab	Inhibitory Antibodies	Inflammation/Immunology Cancer
Sotigalimab, a CD40 agonistic monoclonal antibody. Sotigalimab binds CD40 with high affinity and activates antigen-presenting cells, thereby stimulating cancer-specific T cell responses. Sotigalimab is mainly used in the study of metastatic pancreatic cancer and metastatic melanoma .

HY-P99286

Drozitumab PRO 95780; rhuMAb-DR 5; Anti-Human DR5 Recombinant Antibody	Apoptosis	Cancer
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma .

HY-P99593

Sofituzumab vedotin DMUC5754A	Antibody-Drug Conjugates (ADCs)	Cancer
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer .

HY-P99672

Istiratumab MM 141; MM-005	IGF-1R EGFR	Cancer
Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers .

HY-P99593A

Sofituzumab vedotin (solution) DMUC5754A (solution)	Antibody-Drug Conjugates (ADCs)	Cancer
Sofituzumab vedotin (DMUC5754A) (solution) is an antibody-drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-cleavable linker .

HY-P9974

Vantictumab OMP-18R5	Wnt	Cancer
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .

HY-P99667

Ipafricept 1 Publications Verification OMP-54F28; FZD8-Fc	Wnt	Cancer
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .

Cat. No.	Product Name		Classification

HY-159511

Hedgehog IN-7		Azide
Hedgehog IN-7 (Compound 8g), a purine derivative, acts as an inhibitor of Hedgehog, capable of reducing the expression of Hedgehog genes and inhibiting Hedgehog signaling. Hedgehog IN-7 has significant cytotoxicity and selectivity towards the Hedgehog pathway-dependent pancreatic cancer cell Mia-PaCa-2 cells and can be used in the research of pancreatic cancer .

HY-147526

RM-581		Alkynes
RM-581, an aminosteroid derivative, has potent anticancer activity in different types of cancer, including high fatality pancreatic cancer . RM-581 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name		Classification

HY-160061

P12FR2 aptamer sodium		Aptamers
P12FR2 aptamer sodium is a 2'-fluoropyrimidine-modified RNA aptamer targeting human PAUF with an estimated apparent KD of 77 nM. P12FR2 aptamer sodium inhibits PAUF-induced migration of PANC-1 (human pancreatic cancer cells) in wound healing assays and suppresses tumor growth in a mouse CFPAC-1 pancreatic cancer model .

HY-164185

P12FR2 sodium		Aptamers
P12FR2 sodium is an aptamer targeting human pancreatic adenocarcinoma up-regulated factor (PAUF). P12FR2 specifically binds to human PAUF with an estimated apparent KD of 77 nM. P12FR2 inhibits PAUF-induced PANC-1 cell migration and pancreatic cancer xenograft growth.

HY-164186

M9-5 sodium		Aptamers
M9-5 sodium is an aptamer targeting cyclophilin B. M9-5 binds to the MiaPaCa-2 secretory protein with high affinity and can be used as a blood biomarker for the detection of pancreatic cancer.

HY-160045

AP1153 aptamer sodium		Aptamers
AP1153 aptamer sodium is a DNA aptamer that specifically binds to the cholecystokinin receptor CCKBR (Kd: ~15 pM), but does not activate CCKBR-related signaling pathways. AP1153 aptamer sodium is internalized by pancreatic ductal adenocarcinoma (PDAC) cells in a receptor-mediated manner. AP1153 aptamer sodium can bioconjugate to the surface of fluorescent nanoparticles to facilitate nanoparticle delivery to PDAC tumors in vivo .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Pancreatic Cancer

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

NaturalProducts

Click Chemistry

Oligonucleotides

Natural
Products